General

The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. Hostenkamp G et al. Soc Sci Med. 2015 Feb 7;130C:162-171. doi: 10.1016/j.socscimed.2015.02.003. [Epub ahead of print]. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Ashjian E et al. J Oncol Pharm Pract. 2015 Feb 17. pii: 1078155215572036. [Epub ahead of print]. Advance…

Complications of myeloma and its treatments

Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment. Wang L et al. Clin J Oncol Nurs. 2015 Feb 1;19(1):E4-7. doi: 10.1188/15.CJON.E4-E7. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Peng L et al. Support Care Cancer. 2015 Feb 13. [Epub ahead of print]. Renal insufficiency retains adverse prognostic implications despite renal function improvement following…

Supportive care

Plasmapheresis in cast nephropathy: yes or no? Madore F. Curr Opin Nephrol Hypertens. 2015 Jan 14. [Epub ahead of print]. Antimicrobial peptides: an alternative for innovative medicines? da Costa JP et al. Appl Microbiol Biotechnol. 2015 Jan 15. [Epub ahead of print]. Outcomes following surgical intervention for impending and gross instability caused by multiple myeloma in the spinal column. Zadnik PL et al. J…

General

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Arroz M et al. Cytometry B Clin Cytom. 2015 Jan 23. doi: 10.1002/cyto.b.21228. [Epub ahead of print]. Novel agents have a significant impact on survival of patients with multiple myeloma. Lamm W et al. Wien Klin Wochenschr. 2015 Jan 22. [Epub ahead of print]. Multiple myeloma. Mehta A. Hematology. 2015 Jan;20(1):58-9. doi: 10.1179/1024533214Z.000000000333.…

Complications of myeloma and its treatments

Pleural effusion formation in the course of myeloma. Comert M etal. Arch Bronconeumol. 2015 Jan 22. pii: S0300-2896(14)00242-7. doi: 10.1016/j.arbres.2014.05.009. [Epub ahead of print]. Diagnosis of monoclonal gammopathy of renal significance. Bridoux F et al. Kidney Int. 2015 Jan 21. doi: 10.1038/ki.2014.408. [Epub ahead of print]. Paralytic ileus following “subcutaneous bortezomib” therapy: focus on the clinical emergency-report of two cases. Mele…

Current treatments

An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma. Nishihori T et al. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12509. [Epub ahead of print]. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myelomanot eligible for or who deferred autologous stem cell transplantation.…

General

The Role Of P2X Receptors In Bone Biology. Jorgensen NR et al. Curr Med Chem. 2014 Dec 14. [Epub ahead of print]. A joined role of canopy and reversal cells in bone remodeling – Lessons from glucocorticoid-induced osteoporosis. Jensen PR et al. Bone. 2014 Dec 10. pii: S8756-3282(14)00456-6. doi: 10.1016/j.bone.2014.12.004. [Epub ahead of print]. Multiple myeloma and chronic leukaemias in 2014: Improved…

Complications of myeloma and its treatments

Bortezomib-induced acute pancreatitis: Case report and review of the literature. Talamo G et al. J Oncol Pharm Pract. 2014 Dec 15. pii: 1078155214563813. [Epub ahead of print]. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Teh BW et al. Support Care Cancer. 2014 Dec…